The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

被引：0

作者：

Al-Sawaf, Othman ^{[1
,2
,3
]}

Fuerstenau, Moritz ^{[1
,2
,3
]}

Giza, Adam ^{[1
,2
,3
]}

Robrecht, Sandra ^{[1
,2
,3
]}

Von Tresckow, Julia ^{[4
]}

Fink, Anna Maria ^{[1
,2
,3
]}

Simon, Florian ^{[1
,2
,3
]}

Tausch, Eugen ^{[5
]}

Schneider, Christof ^{[6
]}

Sivcheva, Liliya ^{[7
]}

Schwarer, Anthony ^{[8
]}

Loscertales, Javier ^{[9
]}

Weinkove, Robert ^{[10
]}

Strumberg, Dirk ^{[11
]}

Kilfoyle, Allanah R. ^{[12
]}

Juliusson, Gunnar ^{[13
]}

Da Cunha-Bang, Caspar ^{[14
]}

Illmer, Thomas

Gregor, Michael ^{[15
]}

Thornton, Patrick ^{[16
]}

Janssens, Ann ^{[17
]}

Tadmor, Tamar ^{[18
]}

Lindstrom, Vesa ^{[19
,20
]}

Staber, Philipp Bernhard ^{[21
]}

Levin, Mark-David ^{[22
]}

Wendtner, Clemens-Martin ^{[23
]}

Kreuzer, Karl-Anton ^{[1
,2
,3
]}

Ritgen, Matthias ^{[24
]}

Stilgenbauer, Stephan ^{[25
]}

Kater, Arnon P. ^{[26
]}

Niemann, Carsten Utoft ^{[27
]}

Fischer, Kirsten ^{[1
,2
,3
]}

Eichhorst, Barbara F. ^{[28
]}

Hallek, Michael ^{[29
]}

机构：

[1] Univ Cologne, Fac Med, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

[3] Univ Cologne, German CLL Study Grp, Cologne, Germany

[4] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Clin Hematol & Stem Cell Transplantat, Essen, Germany

[5] Ulm Univ, Div CLL, Dept Internal Med 3, Ulm, Germany

[6] Univ Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[7] Multiprofile Hosp Act Treatment HristoBotev, Dept Internal Med 1, Vratsa, Bulgaria

[8] Box Hill Hosp, Melbourne, Vic, Australia

[9] Hosp Univ La Princesa, Madrid, Spain

[10] Wellington Rerenga Ora Blood & Canc Ctr, Capital & Coast Dist Hlth Board, Wellington, New Zealand

[11] Marien Hosp, Herne, Germany

[12] Palmerston North Hosp, Palmerston North, New Zealand

[13] Lund Univ Canc Ctr, Dept Hematol, Lund, Sweden

[14] Rigshosp, Copenhagen, Denmark

[15] Cantonal Hosp Lucerne, Div Hematol, Luzern, Switzerland

[16] Beaumont Hosp, Canc Trials Ireland, Dept Haematol, RCSI, Dublin, Ireland

[17] Univ Hosp Leuven, Leuven, Belgium

[18] Bnai Zion Med Ctr, Hematol, Haifa, Israel

[19] Helsinki Univ Hosp, Dept Hematol, Ctr Comprehens Canc, Helsinki, Finland

[20] Univ Helsinki, Helsinki, Finland

[21] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med 1, Vienna, Austria

[22] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands

[23] German CLL Study Grp, Munich Clin Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany

[24] Univ Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[25] Univ Hosp Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[26] Acad Med Ctr, Amsterdam, Netherlands

[27] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark

[28] Univ Cologne, Cologne, Germany

[29] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188827

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：8

共 50 条

[21] Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
Flinn, Ian W.
Gribben, John G.
Dyer, Martin J. S.
Wierda, William G.
Maris, Michael B.
Furman, Richard R.
Hillmen, Peter
Jones, Jeffrey
Iyer, Swami P.
Jones, Surai
Jiang, Yanwen
Pignataro, Daniela Soriano
Humphrey, Kathryn
Mobasher, Mehrdad
Kipps, Thomas J.
BLOOD, 2017, 130
[22] IS OBINUTUZUMAB COST-EFFECTIVE FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES?
Reyes, C.
Veenstra, D.
Ramsey, S.
HAEMATOLOGICA, 2014, 99 : 488 - 488
[23] Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations
Reda, G.
Orofino, N.
Cassin, R.
Sciume, M.
Fattizzo, B.
Cortelezzi, A.
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (06) : 865 - 873
[24] MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (vol 18, pg 3689, 2022)
Ryan, Christine E.
Davids, Matthew S.
Hermann, Richard
Shahkarami, Mina
Biondo, Juliana
Abhyankar, Sarang
Alhasani, Hasan
Sharman, Jeff P.
Mato, Anthony R.
Roeker, Lindsey E.
FUTURE ONCOLOGY, 2023,
[25] Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial
Al-Sawaf, Othman
Gentile, Brittany
Devine, Jacob
Zhang, Can
Sail, Kavita
Tandon, Maneesh
Fink, Anna-Maria
Kutsch, Nadine
Wendtner, Clemens-Martin
Eichhorst, Barbara
Hallek, Michael
Fischer, Kirsten
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (09) : 1112 - 1119
[26] High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia
Al-Sawaf, Othman
Lilienweiss, Esther
Bahlo, Jasmin
Robrecht, Sandra
Fink, Anna-Maria
Patz, Michaela
Tandon, Maneesh
Jiang, Yanwen
Schary, William
Ritgen, Matthias
Tausch, Eugen
Stilgenbauer, Stephan
Eichhorst, Barbara
Fischer, Kirsten
Hallek, Michael
Kreuzer, Karl-Anton
BLOOD, 2020, 135 (11) : 866 - 870
[27] Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison
Andrasiak, Iga
Rybka, Justyna
Knopinska-Posluszny, Wanda
Wrobel, Tomasz
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (05): : 268 - 273
[28] Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
Byrd, John C.
Flynn, Joseph M.
Kipps, Thomas J.
Boxer, Michael
Kolibaba, Kathryn S.
Carlile, David J.
Fingerle-Rowson, Guenter
Tyson, Nicola
Hirata, Jamie
Sharman, Jeff P.
BLOOD, 2016, 127 (01) : 79 - 86
[29] Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Lei, Matthew M.
Sorial, Mark N.
Lou, Uvette
Yu, Michelle
Medrano, Andrea
Ford, Josie
Nemec, Ronald A.
Abramson, Jeremy S.
Soumerai, Jacob D.
LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 653 - 659
[30] Total cost of care with 12 months fixed duration of venetoclax plus obinutuzumab in previously-untreated chronic lymphocytic leukemia (CLL) patients
Cho, Sang Kyu
Manzoor, Beenish
Sail, Kavita
Ravelo, Arliene
Shapouri, Sheila
Sharmokh, Simon
Kapustyan, Tatyana
Johnson, Scott
Parise, Helene
Virabhak, Suchin
Davids, Matthew
LEUKEMIA & LYMPHOMA, 2020, 61 : 57 - 57

← 1 2 3 4 5 →